License Agreements (Details Textual) - USD ($)			1 Months Ended										12 Months Ended
	Feb. 01, 2020	Mar. 08, 2019	Nov. 20, 2019	Sep. 30, 2019	Aug. 19, 2019	Jul. 31, 2019	Jul. 29, 2019	May 31, 2019	Mar. 31, 2019	Aug. 31, 2018	Jul. 31, 2018	May 18, 2018	Dec. 31, 2019	Dec. 31, 2018
Commercial evaluation sublicense and option agreement description		The Company entered into a commercial evaluation sublicense and option agreement with the University of Maryland, Baltimore (“UMD”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”). Pursuant to the agreement, the Company paid an initial option and material access fee of $5,000 to UMD and $5,000 to Isoprene.
Recorded expense value									$ 10,000
Issuance of shares														12,500
License Agreement [Member]
Initial fee												$ 5,000
Annual license fee												5,000
Minimum annual royalty												$ 5,000
Expires license term												10 years
Recorded expense value										$ 2,500
License maintenance fee											$ 5,000	$ 2,500
License Agreement [Member] | Maximum [Member]
Milestone payments												$ 120,000
George Washington University [Member]
Option exercise fee						$ 2,500
Sponsored research agreement, description							Pursuant to the terms of the Sponsored Research Agreement, GWU granted the Company a non-exclusive, license to certain of GWU's intellectual property. The Company has agreed to pay GWU for all costs incurred in connection with the research; provided, however, such costs shall not exceed approximately $0.3 million. The Sponsored Research Agreement shall terminate on June 30, 2020 unless extended by the parties. The Sponsored Research Agreement may be terminated by either party upon 30 days written notice.
George Washington University [Member] | Subsequent Event [Member]
License initiation fee	$ 10,000
Warrants term	10 years
Licensed product, description	(i) $75,000 per year for the development and commercialization of the GWU Licensed Product, (ii) $2,000 for license maintenance fees on the first anniversary of the Effective Date and (iii) $5,000 for license maintenance fees commencing on the second anniversary of the Effective Date and thereafter. Furthermore, the Company shall be required to pay GWU a sublicense fee equal to a certain percentage of the sum of payments plus the fair market value of all other consideration of any kind received by the Company from sublicensees during each quarter as follows: a 40% sublicense fee until the first anniversary of the Effective Date, a 30% sublicense fee until the third anniversary of the Effective Date and a 20% sublicense fee after the third anniversary of the Effective Date; provided, however, such sublicense fee shall exclude certain fees paid to the Company such as certain royalties, equity investments, loan proceeds and sponsored research funding. Subject to the execution of a definitive license agreement with GWU, the Company shall also pay GWU milestone payments of up to an aggregate of $90,000 and sales based royalties at a low single digit percentage, subject to certain minimum royalty requirements. In addition, during each Option Exercise Period and Renewal Period (as defined in the Research Option Agreement) the Company shall pay GWU, on a quarterly basis, for all costs and expenses related to the GWU Licensed Patents (the "Patent Costs").
George Washington University [Member] | Subsequent Event [Member] | Licensed Patents [Member]
Patents paid	$ 2,500
North Carolina State University [Member]
License initiation fee			$ 25,000
Recorded expense value													$ 25,000
North Carolina State University [Member] | Maximum [Member]
Milestone payments			585,000
Minimum annual royalty			50,000
North Carolina State University [Member] | Minimum [Member]
Minimum annual royalty			$ 0
Chelexa BioSciences, Inc. [Member]
Milestone payments													3,500,000
Recorded expense value														$ 100,000
Issuance of shares														213,166
Isoprene-Hoth Option [Member]
Option exercise fee													20,000
UMD-Hoth Option [Member]
Option exercise fee													$ 20,000
Zylö Therapeutics Inc. [Member]
Sublicense Agreement, description					(i) an upfront license fee of $50,000; (ii) sales-based royalties at percentages which range from high single digits to low double digits, with low sales volumes being subject to lower royalty rates; and total milestone payments of up to $13.5 million. In addition, within 45 days of the Company’s next equity financing pursuant to which the Company receives gross proceeds of at least $1 million, the Company shall purchase equity securities of Zylö in an amount equal to $60,000.
Recorded expense value				$ 40,000				$ 10,000